Bioscience of Microbiota, Food and Health
Online ISSN : 2186-3342
ISSN-L : 2186-3342
Full Paper
Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II—a exploratory trial
Hidenori OHKUBO, Takaomi KESSOKU, Kosuke TANAKA, Kota TAKAHASHI, Tomohiro TAKATSU, Tsutomu YOSHIHARA, Noboru MISAWA, Keiichi ASHIKARI, Akiko FUYUKI, Shingo KATO, Takuma HIGURASHI, Kunihiro HOSONO, Masato YONEDA, Toshihiro MISUMI, Satoru SHINODA, Vincenzo STANGHELLINI, Atsushi NAKAJIMA
Author information
Keywords: chronic intestinal pseudo-obstruction (CIPO), rifaximin (RFX), small intestinal bacterial overgrowth (SIBO), systemic scleroderma (SSc)
JOURNAL OPEN ACCESS
Supplementary material

2024 Volume 43 Issue 2 Pages 135-144

Browse “Advance online publication” version
Details
Download PDF (977K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

Chronic intestinal pseudo-obstruction (CIPO) is a rare intractable disease with limited treatment options. Small intestinal bacterial overgrowth (SIBO) often co-occurs with several diseases, including CIPO. While rifaximin (RFX) is effective in treating SIBO, its efficacy for CIPO remains unclear. Here, we aimed to investigate the efficacy and safety of RFX in adult patients with CIPO. Twelve patients were randomly assigned to receive RFX (400 mg three times daily, n=8) or a placebo (PBO, n=4) for 4 weeks. The global symptom score for abdominal bloating (GSS-bloating) and an original whole gastrointestinal symptoms score (O-WGSS) were collected, and a glucose hydrogen breath test (GHBT) and abdominal computed tomography (CT) were performed. No significant differences were observed in the primary endpoint. GSS-bloating improved by 75% and 25% in the PBO and RFX groups, respectively, and O-WGSS improved by 25% in both groups. No significant differences were observed in secondary and other endpoints, including the SIBO eradication rate in the GHBT and small intestinal volume on CT. In a post hoc analysis of SIBO-positive patients with CIPO (4/4 and 4/8 in the PBO and RFX groups), SIBO was eradicated in 25% and 75% of the patients (PBO and RFX groups, respectively) at the end of treatment, indicating a high eradication rate in the RFX group. Furthermore, the small intestinal gas volume decreased in the RFX group, and no severe adverse events occurred. Although no significant improvements were observed in subjective indicators, RFX may be beneficial in alleviating SIBO and reducing the small intestinal gas volume in SIBO-positive patients with CIPO.

Content from these authors
© 2024 by BMFH Press

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
Favorites & Alerts

Recently viewed articles
Predecessor

Bifidobacteria and Microflora

Bioscience and Microflora

Share this page
feedback
 Top